Eribulin Mesylate Medication Information

Get detailed information on Eribulin Mesylate, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it.

The updated prescription information on Eribulin Mesylate provides an overview of possible side effects, precautions, warnings, and storage tips.

You'll also find brand names used in india and internationally, along with pricing details. For further clarification, consult your healthcare provider.

Generic Name : Eribulin Mesylate

Pronunciation : ER-i-BUE-lin

ICD Code : Y43.3 Therapeutic Classification : Chemotherapy

Trade Names/Brand Names of Eribulin Mesylate

International :

Halaven

Why is Eribulin Mesylate Prescribed? (Indications)

This medication is an anticancer agent, prescribed for breast cancer. It prevents the growth and spread of cancer cells in the body.

When should Eribulin Mesylate not be taken? (Contraindications)

Contraindicated in patients with irregular heartbeat, and hypersensitivity.

What is the dosage of Eribulin Mesylate?

IV- The recommended dose is 1.4 mg/m² over 2 to 5 minutes infusion on days 1 and 8 of a 21-day cycle.

How should Eribulin Mesylate be taken?

It comes as a solution for injection to be administered by a healthcare provider into the vein.

What are the warnings and precautions for Eribulin Mesylate?

• Caution should be exercised in patients with history of liver, kidney, heart problems, any allergy, who are taking other medications, during pregnancy and breastfeeding.

• It may cause dizziness, do not drive a car or operate machinery while taking this medication.

• It may cause burning, numbness, or tingling in the hands or feet; if it is so consult with your doctor.

• Avoid contact with people who have infections.

• Avoid live vaccination during the treatment period.

• It may reduce platelet counts; avoid injury or bruising.

• Monitor complete blood cell counts and heart function regularly while taking this medication.

What are the side effects of Eribulin Mesylate?

Most Common - Decrease in white blood cells, anemia, weakness, fatigue, hair loss, nerve disease, nausea, and constipation.
Central Nervous system - Headache.
General - Weakness, fatigue and fever.
Gastrointestinal - Diarrhea and vomiting.
Musculoskeletal - Joint/muscle pain, back pain, bone pain and pain in extremity.
Metabolic - Loss of appetite and decreased weight.
Respiratory - Cough and difficulty in breathing.
Genitourinary - Urinary tract infection.